Larvol Delta - Acumen-Pharmaceuticals-Presents-LateBreaker-Phase-1-Updates-Exploring-Novel-Target-Engagement-Dosing-Regimen-and-Safety-Findings-for-ACU193-in-Early-Alzheimers-Disease-at-the-16th-Annual-Clinical-Trials-on-Alzheimers-Disease

ACU193 IV - Acumen Pharma

https://www.globenewswire.com/news-release/2023/10/27/2768456/0/en/Acumen-Pharmaceuticals-Presents-Late-Breaker-Phase-1-Updates-Exploring-Novel-Target-Engagement-Dosing-Regimen-and-Safety-Findings-for-ACU193-in-Early-Alzh

Oct 27, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next